Supplementary Materials

This PDF file includes:

  • Fig. S1. Mean change from baseline in CS up to 96 weeks after administration of rAAV2/2-ND4 gene therapy.
  • Table S1. Baseline characteristics of subjects enrolled in the REVERSE study.
  • Table S2. Change from baseline to week 96 for CS, HVF perimetry and OCT parameters.
  • Table S3. Visual responders at week 96.
  • Table S4. Change in vision-related quality of life at week 96.
  • Acknowledgements—Study Teams
  • Author contributions

[Download PDF]